RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Hepatoblastoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Hepatoblastoma in a young adult: Unusual presentation of paediatric malignancy
Rafael Souza, Eurorad (14 October 2026)
https://doi.org/10.35100/eurorad/case.19733
- 2.
Spatially resolved tumor-microenvironment architecture defines therapeutic response in unresectable hepatoblastoma
Zahra Mesrizadeh et al., bioRxiv (Cold Spring Harbor Laboratory) (13 October 2026)
https://doi.org/10.64898/2026.10.10.758234
- 3.
Combined Portal and Hepatic Vein Embolization to Enhance the Future Liver Remnant in Pediatric Hepatoblastoma.
Bravo R Eduardo et al., Journal of vascular and interventional radiology : JVIR (8 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42849869/
- 4.
Quantitative analysis of tumor perfusion via contrast-enhanced ultrasound to predict the neoadjuvant chemotherapy efficacy for children with hepatoblastoma.
Chen Meixi et al., Journal of ultrasound (4 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42829901/
- 5.
Fat-containing liver lesions expanding the magnetic resonance imaging signature of hepatoblastoma.
Ozer Gozde et al., Pediatric radiology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42340424/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04320888
- 2.
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04195555
- 3.
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582 · Active (not recruiting) · Phase 3 · Children's Oncology Group
Up to age 30
https://clinicaltrials.gov/study/NCT03533582
- 4.
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT03213652
- 5.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT03155620
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Hepatoblastoma
Hepatoblastoma is a rare cancer that starts in the liver, almost always in babies and young children. It often causes a swelling or lump in the abdomen. Treatment usually involves surgery to remove the tumour, together with chemotherapy, and a liver transplant is sometimes needed. Research continues into safer and more effective treatments.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Hepatoblastoma?
Hepatoblastoma is a rare cancer that starts in the liver, almost always in babies and young children. It often causes a swelling or lump in the abdomen. Treatment usually involves surgery to remove the tumour, together with chemotherapy, and a liver transplant is sometimes needed. Research continues into safer and more effective treatments.
How many clinical trials are available for Hepatoblastoma?
RareWays currently indexes 54 clinical trials for Hepatoblastoma, of which 9 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Hepatoblastoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Hepatoblastoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.